Will the recent IPOs of Pacific Biosciences, a cut-rate Aegerion Pharmaceuticals, and a reportedly massive debut by a Chinese drug maker w...

The liver disease community – if not the investment community – has largely moved on from the novelty of comparing Vertex Pharmaceuticals...

Funny what happens at Halloween. Yours truly was looking up the latest on the French doctors' pay-for-performance scheme, the CAPI ( C...

It's always nice to see option buyers out there Sweatin to the Oldies . Last week's exercisers Cephalon and Purdue followed throu...

Any drug developer who showed up at the Royal Society of Medicine in London this morning could have been forgiven for thinking Christmas has...

Just when you think everything that can be said about Avandia has been said, along comes an impromptu, verbal sparring match between high-l...

As 2010’s days grow shorter, the pharmaceutical industry’s larger players face fundamental challenges, both in how they invest in internal r...

There was an unexpected twist last weekend in the health care reform implementation: Docs based in the Delaware Valley got hit harder than e...

Advisory committees are always interesting, but you really have to expect the unexpected when Public Citizen Health Research Group Director ...

Europe's biotechs have long suffered from a lack of decent analyst coverage; now there's even less. Piper Jaffray's six-strong ...